Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia

, MT Newswires -  11:10 AM ET 3/31/2025 Company News

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

11:10 AM EDT, 03/31/2025 (MT Newswires) -- Apollomics ( APLM ) and LaunXP International said Monday that they signed a development and commercialization agreement in Asia covering Apollomics' ( APLM ) vebreltinib c-Met inhibitor for the treatment of non-small cell lung cancer.

The deal entitles Apollomics ( APLM ) to receive $10 million in upfront payments within 60 days in exchange for granting LaunXP exclusive development and commercialization rights over vebreltinib, in combination with an EGFR inhibitor, in Asia excluding mainland China, Hong Kong, and Macau, the companies said.

Apollomics ( APLM ) will also be entitled to up to $50 million in milestone payments, as well as royalties on net product sales, the companies added.

Vebreltinib remains under clinical investigation and is not yet approved for use in any other regions in the world, they said.

Shares of Apollomics ( APLM ) jumped 12% in recent trading.

Price: 8.29, Change: +0.89, Percent Change: +12.03

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.